Corient Private Wealth
NBIX icon

Corient Private Wealth’s Neurocrine Biosciences NBIX Stock Holding History

Corient Private Wealth’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.22M Buy
54,680
+9,645
+21% +$1.43M 0.01% 670
2026
Q1 		$5.91M Buy
45,035
+39,678
+741% +$5.26M 0.01% 788
2025
Q4 		$760K Buy
5,357
+1,352
+34% +$196K ﹤0.01% 1648
2025
Q3 		$562K Sell
4,005
-866
-18% -$117K ﹤0.01% 1732
2025
Q2 		$612K Buy
4,871
+671
+16% +$77K ﹤0.01% 1597
2025
Q1 		$465K Sell
4,200
-3,727
-47% -$472K ﹤0.01% 1635
2024
Q4 		$1.08M Buy
7,927
+3,094
+64% +$383K ﹤0.01% 1282
2024
Q3 		$557K Buy
4,833
+397
+9% +$54.4K ﹤0.01% 1676
2024
Q2 		$611K Buy
4,436
+617
+16% +$84.6K ﹤0.01% 1542
2024
Q1 		$527K Buy
3,819
+637
+20% +$87K ﹤0.01% 1603
2023
Q4 		$419K Buy
3,182
+23
+0.7% +$2.65K ﹤0.01% 1697
2023
Q3 		$355K Buy
3,159
+110
+4% +$11.6K ﹤0.01% 1662
2023
Q2 		$288K Sell
3,049
-2,145
-41% -$210K ﹤0.01% 1720
2023
Q1 		$526K Buy
+5,194
New +$540K ﹤0.01% 1360

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Corient Private Wealth's NBIX Position: Q2 2026 in Review

Corient Private Wealth increased its Neurocrine Biosciences (NBIX) stake by 21% in Q2 2026, buying an estimated $1.43M and bringing the position to 54,680 shares worth $9.22M. The position accounts for 0.01% of the portfolio, ranked #670.

Corient Private Wealth first reported a position in NBIX in Q1 2023 and has held it in 14 quarters since. 779 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Corient Private Wealth held 54,680 shares of Neurocrine Biosciences worth $9.22M as of Q2 2026.
  • Corient Private Wealth bought 9,645 Neurocrine Biosciences shares in Q2 2026, an estimated $1.43M.
  • Neurocrine Biosciences made up 0.01% of Corient Private Wealth's portfolio in Q2 2026, its #670 holding.
  • Corient Private Wealth first reported a position in Neurocrine Biosciences in Q1 2023 and has held it in 14 quarters since.
  • 779 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.